Identification and structure of AIMP2-DX2 for therapeutic perspectives

키워드

참고문헌 (53)

1. Park SG, "Functional expansion of aminoacyl-tRNA synthetases and their interacting factors : new perspectives on housekeepers", Trends Biochem Sci, 30, pp.569~574 (2005)
2. Han JM, "AIMP2", p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53, 2008, pp.105, 11206~11211
3. Kim DG, "Oncogenic mutation of AIMP2", p38 inhibits its tumor-suppressive interaction with Smurf2, 2016, pp.76, 3422~3436
4. Yum MK, "AIMP2 controls intestinal stem cell compartments and tumorigenesis by modulating Wnt", -catenin signaling, 2016, pp.76, 4559~4568
5. Choi JW, "Cancer-associated splicing variant of tumor suppressor AIMP2", p38 : pathological implication in tumorigenesis, 2011, pp.7, e1001351~
6. Mayer MP, "Hsp70 chaperone dynamics and molecular mechanism", Trends Biochem Sci, 38, pp.507~514 (2013)
7. Park SG, "Aminoacyl-tRNA synthetase-interacting multifunctional proteins(AIMPs) : a triad for cellular homeostasis", IUBMB life, 62, pp.296~302 (2010)
8. Park SG, "Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis", JBC, 277, pp.45243~45248 (2002)
9. Park H, "Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43", Cytokine, 20, pp.148~153 (2002)
10. Matschurat S, "Regulation of EMAP II by hypoxia", Am J Pathol, 162, pp.93~103 (2003)
11. Park SG, "The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair", Am J Pathol, 166, pp.387~398 (2005)
12. Park SG, "Hormonal activity of AIMP1", p43 for glucose homeostasis, 2006, pp.103, 14913~14918
13. Kim E, "AIMP1", p43 protein induces the maturation of bone marrow-derived dendritic cells with T helper type 1-polarizing ability, 2008, pp.180, 2894~2902
14. Ko YG, "A cofactor of tRNA synthetase, p43, is secreted to up-regulate proinflammatory genes", JBC, 276, pp.23028~23033 (2001)
15. Park H, "Monocyte cell adhesion induced by a human aminoacyl-tRNA synthetaseassociated factor, p43 : identification of the related adhesion molecules and signal pathways", J Leukoc Biol, 71, pp.223~230 (2002)
16. Kim E, "The novel cytokine p43 induces IL-12 production in macrophages via NF-B activation, leading to enhanced IFN-production in CD4+ T cells", J Immunol, 176, pp.256~264 (2006)
17. Kim JY, "p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex : implications for its physiological significance", Proc Natl Acad Sci U S A, 99, pp.7912~7916 (2002)
18. Duncan R, "A sequencespecific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif", Genes Dev, 8, pp.465~480 (1994)
19. Kim MJ, "Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation", Nat Genet, 34, pp.330~336 (2003)
20. Li X, "TNF-RII and c-IAP1mediate ubiquitination and degradation of TRAF2", Nature, 416, pp.345~347 (2002)
21. Choi JW, "AIMP2 promotes TNF-dependent apoptosis via ubiquitin-mediated degradation of TRAF2", J Cell Sci, 122, pp.2710~2715 (2009)
22. Han JM, "Hierarchical network between the components of the multi-tRNA synthetase complex : implications for complex formation", JBC, 281, pp.38663~38667 (2006)
23. Kim JH, "Aminoacyl-tRNA Synthetases in Biology and Medicine", pp.119~144 (2014)
24. Park BJ, "The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM", ATR, 2005, pp.120, 209~221
25. Kim HJ, "Structural and functional roles of AIMP2 and TRAF2 in TNF-signaling", Korean J Life Sci, 30, pp.106~112 (2020)
26. Ku J, "Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer", Commun Biol, 3, pp.630~ (2020)
27. Jung JY, "Ratio of autoantibodies of tumor suppressor AIMP2 and its oncogenic variant is associated with clinical outcome in lung cancer", J Cancer, 8, pp.1347~ (2017)
28. Choi JW, "Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer", J Mol Cell Biol, 4, pp.164~173 (2012)
29. Minami Ki, "Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung", Lung Cancer, 38, pp.51~57 (2002)
30. Chang SH, "Lentiviral vector-mediated shRNA against AIMP2-DX2 suppresses lung cancer cell growth through blocking glucose uptake", Mol Cells, 33, pp.553~562 (2012)
31. Cao Q, "AIMP2-DX2 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma cells", Biomed Res Int, 2018, pp.11~ (2018)
32. Hartl FU, "Molecular chaperones in protein folding and proteostasis", Nature, 475, pp.324~332 (2011)
33. Feder ME, "Heat-shock proteins, molecular chaperones, and the stress response : evolutionary and ecological physiology", Annu Rev Physiol, 61, pp.243~282 (1999)
34. Kumar S, "Targeting Hsp70 : a possible therapy for cancer", Cancer Lett, 374, pp.156~166 (2016)
35. Goloudina AR, "Inhibition of HSP70 : a challenging anti-cancer strategy", Cancer Lett, 325, pp.117~124 (2012)
36. Lim S, "Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development", Nat Chem Biol, 16, pp.31~41 (2020)
37. Vogelstein B, "Surfing the p53 network", Nature, 408, pp.307~310 (2000)
38. Green DR, "Cytoplasmic functions of the tumour suppressor p53", Nature, 458, pp.1127~1130 (2009)
39. Riley T, "Transcriptional control of human p53-regulated genes", Nat Rev Mol Cell Biol, 9, pp.402~412 (2008)
40. Cho HY, "Structural insight into the interaction between p53 TAD1and AIMP2-DX2 by NMR", Biochem Biophys Res Commun, 527, pp.831~838 (2020)
41. Kim HJ, "Oncogenic KRAS : signaling and drug resistance", Cancers, 13, pp.5599~ (2021)
42. Kim DG, "AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis", Nat Commun, 13, pp.2572~ (2022)
43. Oh AY, "Inhibiting DX2-p14", ARF interaction exerts antitumor effects in lung cancer and delays tumor progression, 2016, pp.76, 4791~4804
44. Lee HS, "Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression", Biochem J, 454, pp.411~416 (2013)
45. Cox AD, "Drugging the undruggable RAS : mission possible?", Nat Rev Drug Discov, 13, pp.828~851 (2014)
46. Prior IA, "A comprehensive survey of Ras mutations in cancer", Cancer Res, 72, pp.2457~2467 (2012)
47. Lee S, "2-Aminophenylpyrimidines as novel inhibitors of aminoacyl-tRNA synthetase interacting multifunctional protein 2(AIMP2)-DX2 for lung cancer treatment", J Med Chem, 63, pp.3908~3914 (2020)
48. Sivaraman A, "Synthesis and structure-activity relationships of arylsulfonamides as AIMP2-DX2 inhibitors for the development of a novel anticancer therapy", J Med Chem, 63, pp.5139~5158 (2020)
49. Kim DG, "Anticancer activity of pyrimethamine via ubiquitin mediated degradation of AIMP2-DX2", Molecules, 25, pp.2763~ (2020)
50. Younes M, "Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival", Cancer : Interdisciplinary International Journal of the American Cancer Society, 80, pp.1046~1051 (1997)
51. Lau KS, "Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation", Cell, 129, pp.123~134 (2007)
52. Won YS, "Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme", J Biotechnol, 158, pp.44~49 (2012)
53. Kim S, "AIMP2-DX2 gene and its uses", Patent No. US 8431,393 B2, ~ (2013)

관련 논문AI추천